|
Title
|
Publication |
Date of publication
|
| What, Where, and How to Collect Real-World Data and Generate Real-World Evidence to Support Drug Reimbursement Decision-Making in Asia: A reflection Into the Past and A Way Forward |
International Journal of Health Policy and Management, Vol. 12 - Issue 1 |
March 2023 |
| Horizon Scanning To Nominate Subsidy Evaluation Topics For Medical Technologies: Early Experience From Singapore |
International Journal of Technology Assessment in Health Care, Vol. 38 - Special Issue S1
|
January 2023 |
| Developing a New Region-Specific Preference-Based Measure in East and Southeast Asia |
Value in Health Regional Issues 37 |
November 2022 |
| Real-world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes |
JGH Open, Vol. 7 - Issue 1 |
November 2022 |
| Cost-effectiveness of transcatheter aortic valve implantation in patients with severe symptomatic aortic stenosis of intermediate surgical risk in Singapore |
BMC Health Services Research, Vol. 22 |
August 2022 |
| Measuring Real-World Impact of Subsidy Decision on Sleep Tests Utilisation for the Diagnosis of Obstructive Sleep Apnoea |
Value in Health, Vol. 25 - Issue 7 |
July 2022 |
| Real-World Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulants (NOAC) in Patients with Non-Valvular Atrial Fibrillation (NVAF): A Retrospective Cohort Study in Singapore |
Value in Health, Vol. 25 - Issue 7 |
July 2022 |
| Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study |
Journal of Diabetes & Metabolic Disorders, Vol. 21 |
March 2022 |
Cost-effectiveness of daratumumab in combination with lenalidomide and dexamethasone for relapsed and/or refractory multiple myeloma
|
Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 22 - Issue 2 |
December 2021 |
| Cost-effectiveness analysis of MRI targeted biopsy strategies for diagnosing prostate cancer in Singapore |
BMC Health Services Research, Vol. 21 - Article 909 |
September 2021 |
Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore
|
Vaccine, Vol. 39 - Issue 16 |
April 2021 |
A review of implementation frameworks to operationalize health technology assessment recommendations for medical technologies in the Singapore setting
|
International Journal of Technology Assessment in Health Care, Vol. 37 - Issue 1 |
April 2021 |
| Cost-effectiveness of olaparib maintenance therapy when used with and without restriction by BRCA1/2 mutation status for platinum-sensitive relapsed ovarian cancer |
Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 21 - Issue 3 |
March 2021 |
| A landscape analysis of health technology assessment capacity in the Association of South‑East Asian Nations region |
Health Research and Policy Systems, Vol. 19 |
February 2021 |
|
Cost-effectiveness of pertuzumab and trastuzumab biosimilar combination therapy as initial treatment for HER2-positive metastatic breast cancer in Singapore
|
Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 21 - Issue 3 |
February 2021 |
|
Assessing the cost-effectiveness of mepolizumab as add-on therapy to standard of care for severe eosinophilic asthma in Singapore
|
Journal of Asthma, Vol. 59 - Issue 1 |
October 2020
|
|
Cost-effectiveness of ribociclib as initial treatment for premenopausal women with advanced breast cancer in Singapore
|
Cancer Reports, Vol. 4 - Issue 1 |
October 2020
|
| Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward |
International Journal of Technology Assessment in Health Care, Vol. 36 - Issue 5 |
September 2020 |
|
Cost-effectiveness analysis of osimertinib for first line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore
|
Journal of Medical Economics, Vol 23 - Issue 11 |
September 2020
|
|
Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective
|
Journal of Medical Economics, Vol 23 - Issue 11 |
August 2020
|
|
Cost-effectiveness analysis of pembrolizumab monotherapy versus chemotherapy for previously untreated advanced non-small cell lung cancer
|
Journal of Medical Economics, Vol. 23 - Issue 9 |
June 2020
|
|
Cost-effectiveness analysis of atezolizumab in advanced triple negative breast cancer
|
BMC Health Services Research, 20 - Article 581 |
June 2020
|
|
Cost-effectiveness of sequential urate lowering therapies for the management of gout in Singapore
|
Journal of Medical Economics, Vol. 23 - Issue 8 |
May 2020
|
|
Towards greater impact in health technology assessment: horizon scanning for new and emerging technologies in Singapore
|
International Journal of Technology Assessment in Health Care, Vol. 36 - Issue 4 |
May 2020
|
| Landscape analysis of health technology assessment (HTA): systems and practices in Asia |
International Journal of Technology Assessment in Health Care, Vol. 35 - Issue 6 |
October 2019 |
|
Cost effectiveness analysis of bilateral cochlear implants for children with severe-to-profound sensorineural hearing loss in both ears in Singapore
|
PLOS One |
August 2019
|
|
Health technology assessment and its use in drug policies: Singapore
|
Value in Health, Vol. 18 |
May 2019
|
|
Cost-effectiveness analysis of sunitinib versus interferon-alfa for first-line treatment of advanced and/or metastatic renal cell carcinoma in Singapore
|
International Journal of Technology Assessment in Health Care, Vol. 35 - Issue 2 |
March 2019
|
|
Comparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
|
International Journal of Chronic Obstructive Pulmonary Disease, Vol. 18 |
October 2018
|
|
Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
|
BMC Cancer, Vol. 18 |
March 2018
|
|
Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction
|
Journal of Medical Economics, Vol. 21 - Issue 2 |
October 2017
|